I have to admit, as much as I want to see CTIX become the household name for K, I will be just as happy with a post-phase 2 or phase 3 buyout of K in the tens of billions to a big pharma who is wise enough to put that intellectual property in their pipeline.
My guess is if Leo and Menon have their plans comes to fruition it involves utilizing P and B to partner/license and keep sufficient funding to bring K past phase 2. Once in they are at that point I think they are heavily interested in selling K (with royalties of course) and then riding off into the sunset. I think CTIX will continue, but it will be different people running the day to day operations.